Purchase Order 75N91019P00833

The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $17,852.40 on August 23, 2018, with ultimate completion on August 23, 2019. The order carries fixed-price pricing with economic price adjustment and no set-aside designation. Place of performance is Bethesda, Maryland. The purchase order procures analytical laboratory instrumentation, consumables, or maintenance services typical of Agilent's federal portfolio in analytical chemistry equipment supply.

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $16,259.00 on May 1, 2019, for drugs and biologicals, with ultimate completion on June 3, 2019. Place of performance is Marshtonville, Delaware. The order carries no set-aside designation and is priced on a firm fixed price basis.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for $13,570.50 on July 6, 2020, for drugs and biologicals, with completion on August 6, 2020. Work is performed at Marshtonlon, Delaware. The order carries firm fixed price terms with no set-aside designation.</p>

The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for $16,018.50 on January 31, 2018, with an ultimate completion date of January 25, 2019. The order carries fixed-price pricing with economic price adjustment and no set-aside designation. Place of performance is Bethesda, Maryland. The purchase order procures analytical laboratory instruments and associated consumables or services, consistent with Agilent's role as a supplier of gas chromatography-mass...

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $5,124.04 on May 15, 2018, with ultimate completion on June 30, 2019. No set-aside was used. Place of performance is Bethesda, Maryland. The order is firm fixed price.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $17,430.36 on May 24, 2018, with ultimate completion on June 23, 2018. No set-aside was used. Place of performance is Bethesda, Maryland. The order procures analytical laboratory instrumentation or consumables; the specific product line is not identified in the award record.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $17,430.36 on June 21, 2018, with an ultimate completion date of July 23, 2018. No set-aside was used. Place of performance is Bethesda, Maryland. The order covers analytical laboratory instruments or related consumables and services, consistent with Agilent's product line of gas chromatography-mass spectrometry systems, liquid chromatography-mass spectrometry equipment, and associated supplies.</p>

The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $19,429.50 on June 11, 2018, for firm fixed price delivery completing July 6, 2018. Place of performance is Bethesda, Maryland. No set-aside was used. The order procures analytical laboratory instruments, consumables, or maintenance services consistent with Agilent's role as a supplier of gas chromatography-mass spectrometry systems, liquid chromatography-mass spectrometry equipment, and associated...

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $11,383.20 for a maintenance agreement, with an award date of October 31, 2017 and ultimate completion date of November 30, 2018. Performance is located in Bethesda, Maryland. The order is priced firm fixed price with no set-aside category.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for $16,260.00 on August 31, 2020, for biological and reagent material with a firm fixed price. Place of performance is Marshallton, Delaware, with an ultimate completion date of September 30, 2020. The order was not set-aside and reflects full and open competition.</p>